This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Agenus (AGEN) Q3 Loss Wider Than Expected, Pipeline in Focus
by Zacks Equity Research
Agenus (AGEN) reports a wider third-quarter loss. Revenues earned from collaborations exceeded expectations.
Xoma (XOMA) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Xoma (XOMA) delivered earnings and revenue surprises of -44.74% and 7.95%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
Xoma (XOMA) Q3 Earnings Preview: What's Shaping Up?
by Zacks Equity Research
Xoma (XOMA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Xoma (XOMA) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Xoma (XOMA) delivered earnings and revenue surprises of -15.00% and -50.60%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
AbbVie Presents New Data on Upadacitinib for Crohn's Disease
by Zacks Equity Research
AbbVie (ABBV) announces new data from a phase II study on upadacitinib in adult patients with moderately to severely active Crohn's disease.
Acorda (ACOR) Q4 Earnings Miss Estimates, Revenues Beat
by Zacks Equity Research
Acorda (ACOR) misses on earnings in Q4 but beats on revenue estimates. The company's key drug Ampyra witnesses an increase in sales both year over year and sequentially.
FDA Grants Agios' (AGIO) Leukemia Candidate Priority Review
by Zacks Equity Research
FDA accepts Agios' NDA for its pipeline candidate ivosidenib (AG-120) and sets an action date of Aug 21, 2018.
Ironwood (IRWD) Beats Estimates in Q4 Earnings, Stock Up
by Zacks Equity Research
Ironwood Pharmaceuticals (IRWD) beats estimates on both counts in the fourth quarter. Demand for Linzess continues to rise.
Alkermes (ALKS) Beats Q4 Earnings, Revenue Estimates
by Zacks Equity Research
Alkermes (ALKS) tops earnings and sales estimates in the fourth quarter of 2017 on the back of strong growth of Vivitrol and Aristada. The company provided a decent outlook for 2018.
Zoetis (ZTS) Beats on Q4 Earnings & Sales, Gives 2018 View
by Zacks Equity Research
Zoetis' (ZTS) results exceed both earnings and sales expectations in the fourth quarter of 2017, making it the first animal health company to deliver more than $5 billion in revenues.
Agios (AGIO) Q4 Loss Wider Than Expected, Revenues Slump Y/Y
by Zacks Equity Research
Agios (AGIO) reports wider-than-expected loss in the fourth quarter of 2017. Revenues fall short of expectations. The top line also declines year over year.
Prothena's (PRTA) Loss Narrows in Q4, Pipeline Progresses
by Zacks Equity Research
Prothena (PRTA) reported a narrower-than-expected loss in the fourth quarter as the company continued with its pipeline progress.
Shire (SHPG) Q4 Earnings Beat, Immunology Franchise Strong
by Zacks Equity Research
Shire (SHPG) reported better-than-expected fourth-quarter earnings and also registered strong growth in immunology franchise and newly launched products.
AVEO (AVEO) to Get $2 Million from EUSA Pharma for Fotivda
by Zacks Equity Research
AVEO Oncology (AVEO) is due to receive $2 million from its partner EUSA Pharma as the latter has been granted positive NICE recommendation for Fotivda (tivozanib).
Catalyst Gets Positive FDA Advise on Firdapse NDA Refiling
by Zacks Equity Research
Catalyst (CPRX) posts positive results from a recent Type C meeting with the FDA on resubmitting the new drug application for Firdapse in treating Lambert-Eaton myasthenic syndrome.
Vertex's Third Cystic Fibrosis Treatment Gets FDA Approval
by Zacks Equity Research
Vertex???s (VRTX) FDA approved tezacaftor/ivacaftor combination for cystic fibrosis in patients with certain mutations in the CFTR gene marks the indication???s third treatment.
ImmunoGen (IMGN) Q4 Loss Wider Than Expected, Revenues Grow
by Zacks Equity Research
ImmunoGen (IMGN) reports wider-than-expected loss in Q4. However, higher license and milestone fees drive substantial revenue rise year over year.
FDA Okays J&J's Prostate Cancer Drug in First-Line Setting
by Zacks Equity Research
The FDA lends a nod to the label expansion of Johnson & Johnson's (JNJ) Zytiga in combination with prednisone for metastatic high-risk castration-sensitive prostate cancer.
Theravance, J&J Ink Deal for Inflammatory Intestinal Drug
by Zacks Equity Research
Theravance (TBPH) signs a global collaboration agreement with Johnson & Johnson to jointly develop and commercialize TD-1473 for inflammatory intestinal diseases.
Alexion's (ALXN) Earnings and Sales Beat Estimates in Q4
by Zacks Equity Research
Alexion (ALXN) surpass earnings and sales estimates in the fourth quarter of 2017. The company received FDA approval for label expansion of Soliris in the United States.
Keryx (KERX) Loss Wider Than Expected in Q4, Stock Down
by Zacks Equity Research
Keryx (KERX) reports wider-than-expected loss in Q4. However, sales surpassed estimates.
Pfizer Files for Xtandi in Early Stage Prostate Cancer
by Zacks Equity Research
Pfizer (PFE) announces detailed results from a late-stage study which can expand the label of Xtandi to include early-stage patients. It also files for approval in U.S. and EU.
Allergan's Anti-Infective Drug Avycaz Receives Third FDA Nod
by Zacks Equity Research
The FDA's label expansion approval for Allergan's (AGN) Avycaz marks its third therapeutic indication nod for the anti-infective drug in the United States.
Puma, CANbridge Team Up to Commercialize Nerlynx in China
by Zacks Equity Research
Puma (PBYI) enters an exclusive agreement with CANbridge under which the latter will seek regulatory approval for Nerlynx in China and develop and commercialize it in the region.
Alnylam's (ALNY) RNAi Candidate's NDA Gets Priority Review
by Zacks Equity Research
Alnylam's NDA for lead candidate patisiran is accepted by the FDA and granted priority review. The FDA also set an action date of Aug 11, 2018.